In October 2024, Jensen Huang, the CEO of AI chipmaker Nvidia, commented that the European Union (EU) lags far behind the U.S. and China when it comes to investing in AI. Not long after, French President Emmanuel Macron also told CNN in an exclusive interview that Europe is lagging behind, stating that the bloc is simply “not in the race today.”
…
“With more strict requirements in place for transparency, data governance, human oversight, and accuracy, the EU biotech industry may find it especially difficult to handle the high compliance costs that stricter guidelines impose, potentially hampering biotech innovation in Europe,” said [Cem] Zorlular.
Related on the SLP
“European biotech funding tends to be more conservative, with a lower risk appetite compared to the U.S., where AI-driven biotech startups often receive large-scale funding,” explained [Natalie] Dolphin. “The challenge isn’t a lack of innovation – European research institutions are world-class – but rather a gap in turning that innovation into commercially viable AI-driven solutions. Bridging this gap requires not just more capital but also a shift in investment mindset toward high-risk, high-reward AI ventures.”


















